MK-3475A±MK-1084 bei vollständig reseziertem KRAS G12Cm NSCLC im Stadium IIA-IIIB (N2) (MK-1084-013) (KANDLELIT-013)
Eine Phase-3-, randomisierte, doppelblinde Studie zu adjuvanten MK-1084 plus subkutanem Pembrolizumab und Berahyaluronidase Alfa (MK-3475A) gegenüber adjuvanten Placebo plus MK-3475A bei Teilnehmern mit vollständig reseziertem, KRAS G12C-mutiertem nicht-kleinzelligem Lungenkarzinom im Stadium IIA-IIIB (N2) nach Erhalt entweder von neoadjuvantem Pembrolizumab plus Chemotherapie oder adjuvanter Chemotherapie (KANDLELIT-013)
This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage IIA-IIIB (N2), KRAS G12C-mutant non-small cell lung cancer following receipt of either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The primary goal of the study is to compare adjuvant calderasib plus MK-3475A to adjuvant placebo plus MK-3475A with respect to disease-free survival (DFS) as assessed by the investigator.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-Mail: Trialsites@msd.com
Studienorte
-
-
-
CABA, Argentinien, C1431FWO
- Rekrutierung
- Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0309)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5491160006609
-
CABA, Argentinien, C1199ABB
- Rekrutierung
- Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0306)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +541149590200
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentinien, C1426ANZ
- Rekrutierung
- Instituto Alexander Fleming ( Site 0310)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +541132218900
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentinien, S2000DSV
- Rekrutierung
- Sanatorio Parque ( Site 0311)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5493416955611
-
-
-
-
New South Wales
-
Frenchs Forest, New South Wales, Australien, 2086
- Rekrutierung
- Northern Beaches Hospital ( Site 3009)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +6191055083
-
-
Queensland
-
Woolloongabba, Queensland, Australien, 4102
- Rekrutierung
- Princess Alexandra Hospital ( Site 3012)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61731762111
-
-
Victoria
-
Frankston, Victoria, Australien, 3199
- Rekrutierung
- Peninsula University Hospital ( Site 3011)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61397847777
-
-
-
-
-
São Paulo, Brasilien, 01327-001
- Rekrutierung
- Hospital Alemao Oswaldo Cruz ( Site 0416)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +551135491542
-
-
Ceará
-
Fortaleza, Ceará, Brasilien, 60810-180
- Rekrutierung
- PRONUTRIR ( Site 0425)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +55 (85) 3048-0533
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brasilien, 29043-260
- Rekrutierung
- AFECC ASSOCIACAO FEMININA EDUCACAO COMBATE CANCER ( Site 0414)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5527998469004
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasilien, 30441-070
- Rekrutierung
- Hospital Madre Teresa ( Site 0420)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +553133398115
-
-
Pernambuco
-
Recife, Pernambuco, Brasilien, 52010-075
- Rekrutierung
- Real Hospital Portugues ( Site 0418)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5581996214574
-
-
Rio Grande do Sul
-
Porto Alegree, Rio Grande do Sul, Brasilien, 90050-170
- Rekrutierung
- Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0402)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +555132148107
-
-
São Paulo
-
Santo André, São Paulo, Brasilien, 09060-870
- Rekrutierung
- Faculdade de Medicina do ABC ( Site 0415)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +551149935491
-
Taubaté, São Paulo, Brasilien, 12030-200
- Rekrutierung
- Instituto do Câncer Brasil - Unidade Taubaté ( Site 0424)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5512996706805
-
-
-
-
Region M. de Santiago
-
Lo Barnechea, Region M. de Santiago, Chile, 7691236
- Rekrutierung
- Clínica MEDS La Dehesa ( Site 0509)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5622499 6400
-
Santiago, Region M. de Santiago, Chile, 7560908
- Rekrutierung
- Centro de Oncología de Precisión ( Site 0503)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56953796258
-
Santiago, Region M. de Santiago, Chile, 7500921
- Rekrutierung
- Fundación Arturo López Pérez ( Site 0501)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56224205098
-
Santiago, Region M. de Santiago, Chile, 8420383
- Rekrutierung
- Bradford Hill ( Site 0508)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56229490970
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Rekrutierung
- Peking Union Medical College Hospital ( Site 2105)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 010-69154116
-
Beijing, Beijing Municipality, China, 100044
- Rekrutierung
- Peking University People's Hospital ( Site 2100)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 010-88326666
-
Beijing, Beijing Municipality, China, 100142
- Rekrutierung
- Beijing Cancer hospital ( Site 2106)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 010-88121122
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 404199
- Rekrutierung
- Chongqing University Three Gorges Hospital ( Site 2138)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8613896327099
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- Rekrutierung
- The First Affiliated Hospital Of Fujian Medical University ( Site 2123)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8659187982222
-
Fuzhou, Fujian, China, 350014
- Rekrutierung
- Fujian Cancer Hospital ( Site 2122)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0591-83660063
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Rekrutierung
- Sun Yat-sen University Cancer Center ( Site 2134)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8613560405144
-
-
Guangxi
-
Nanning, Guangxi, China, 530200
- Rekrutierung
- Guangxi Medical University Cancer Hospital ( Site 2115)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0771-5310848
-
-
Hebei
-
Hshijiazhuang, Hebei, China, 050010
- Rekrutierung
- Fourth Hospital Of Hebei Medical University ( Site 2107)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +86 0311 - 86095588
-
-
Hubei
-
Wuhan, Hubei, China, 430048
- Rekrutierung
- Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 2139)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +862783261400
-
Wuhan, Hubei, China, 430000
- Rekrutierung
- Tongji Hospital Tongji Medical,Science & Technology ( Site 2140)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8618872257224
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Rekrutierung
- Xiangya Hospital Central South University ( Site 2136)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8673184327918
-
Changsha, Hunan, China, 410013
- Rekrutierung
- Hunan Cancer Hospital ( Site 2112)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +86073189762210
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Rekrutierung
- The First Affiliated Hospital of Nanchang University ( Site 2121)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +86079188695051
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Rekrutierung
- Affiliated Cancer Hospital of Shandong First Medical University ( Site 2111)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0531-87984777
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200000
- Rekrutierung
- Shanghai Pulmonary Hospital ( Site 2125)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 021-65115006-1027
-
Shanghai, Shanghai Municipality, China, 200032
- Rekrutierung
- Zhongshan Hospital of Fudan University ( Site 2119)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 021131587861
-
Shanghai, Shanghai Municipality, China, 200032
- Rekrutierung
- Fudan University Shanghai Cancer Center ( Site 2137)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 021-64175590
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Rekrutierung
- West China Hospital, Sichuan University ( Site 2142)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8602885422114
-
Chengdu, Sichuan, China, 610041
- Rekrutierung
- Sichuan Cancer hospital ( Site 2101)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8663066886
-
Chengdu, Sichuan, China, 610014
- Rekrutierung
- The Third Peoples Hospital Of Chengdu ( Site 2141)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8602861318720
-
-
Xinjiang
-
Urumuqi, Xinjiang, China, 830054
- Rekrutierung
- The Affiliated Cancer Hospital of Xinjiang Medical ( Site 2110)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8613899913829
-
-
Yunnan
-
Kunming, Yunnan, China, 650118
- Rekrutierung
- Yunnan Province Cancer Hospital ( Site 2131)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +867168178106
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Rekrutierung
- The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 2103)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +86057187236114
-
Hangzhou, Zhejiang, China, 310009
- Rekrutierung
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 2118)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0571-86090073
-
Hangzhou, Zhejiang, China, 310022
- Rekrutierung
- Zhejiang Cancer Hospital ( Site 2117)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0571-88122222
-
Ningbo, Zhejiang, China, 315010
- Rekrutierung
- Ningbo No. 2 Hospital ( Site 2124)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0574-83870375
-
-
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, Frankreich, 13015
- Rekrutierung
- Hopital Nord ( Site 1004)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33491965901
-
-
Calvados
-
Caen, Calvados, Frankreich, 14076
- Rekrutierung
- Centre François Baclesse ( Site 1017)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +330231455050
-
-
Languedoc-Roussillon
-
Montpellier, Languedoc-Roussillon, Frankreich, 34070
- Rekrutierung
- Centre de Cancérologie du Grand Montpellier ( Site 1016)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33 4 30 29 73 96
-
-
Val-de-Marne
-
Créteil, Val-de-Marne, Frankreich, 94010
- Rekrutierung
- Centre Hospitalier Intercommunal ( Site 1019)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33157022101
-
-
-
-
Attica
-
Athens, Attica, Griechenland, 151 25
- Rekrutierung
- Athens Medical Center ( Site 1202)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +302107464642
-
Athens, Attica, Griechenland, 106 76
- Rekrutierung
- Evangelismos General Hospital of Athens ( Site 1204)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +30 21 3204 1000
-
Athens, Attica, Griechenland, 115 27
- Rekrutierung
- THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 1206)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +302107700220
-
Athens, Attica, Griechenland, 115 26
- Rekrutierung
- Errikos Dunant Hospital Center ( Site 1201)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +302107470960
-
Piraeus, Attica, Griechenland, 185 37
- Rekrutierung
- Metaxa Cancer Hospital of Piraeus ( Site 1207)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +306940583449
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, Griechenland, 570 10
- Rekrutierung
- G. Papanikolaou General Hospital ( Site 1203)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0030 231330787476
-
-
-
-
-
Hong Kong, Hongkong
- Rekrutierung
- Queen Mary Hospital ( Site 3100)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 85239103299
-
Hong Kong, Hongkong
- Rekrutierung
- Tuen Mun Hospital ( Site 3102)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +85224685111
-
Hong Kong, Hongkong
- Rekrutierung
- Queen Elizabeth Hospital ( Site 3101)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +85235068888
-
-
-
-
-
Roma, Italien, 00168
- Rekrutierung
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0630156050
-
-
Lombardy
-
Milan, Lombardy, Italien, 20133
- Rekrutierung
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1400)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390223903816
-
Milan, Lombardy, Italien, 20141
- Rekrutierung
- IEO Istituto Europeo di Oncologia ( Site 1405)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390257489482
-
-
-
-
-
Fukushima, Japan, 960-1295
- Rekrutierung
- Fukushima Medical University Hospital ( Site 2202)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-24-547-1111
-
Osaka, Japan, 541-8567
- Rekrutierung
- Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 2208)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-6-6945-1181
-
Yamagata, Japan, 990-9585
- Rekrutierung
- Yamagata University Hospital ( Site 2201)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-23-633-1122
-
-
Aomori
-
Hirosaki, Aomori, Japan, 036-8563
- Rekrutierung
- Hirosaki University Hospital ( Site 2200)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-172-33-5111
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japan, 807-8556
- Rekrutierung
- Hospital of the University of Occupational and Environmental Health, Japan ( Site 2214)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-93-603-1611
-
-
Oita Prefecture
-
Yufu, Oita Prefecture, Japan, 879-5593
- Rekrutierung
- Oita University Hospital ( Site 2215)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-97-549-4411
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1191
- Rekrutierung
- Kansai Medical University Hospital ( Site 2209)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-72-804-0101
-
-
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1C 6Z8
- Rekrutierung
- Moncton Hospital ( Site 0200)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 5068575104
-
-
Quebec
-
Chicoutimi, Quebec, Kanada, G7H 5H6
- Rekrutierung
- CIUSSS- saguenay-Lac-Saint-Jean ( Site 0216)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 418 541-1000
-
Montreal, Quebec, Kanada, H2X 3E4
- Rekrutierung
- Centre Hospitalier de l'Université de Montréal ( Site 0219)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 5148908000x26832
-
-
-
-
Antioquia
-
Medellín, Antioquia, Kolumbien, 050034
- Rekrutierung
- Promotora Médica Las Américas S.A. ( Site 0602)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5734093935461
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Kolumbien, 111321
- Rekrutierung
- Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 0603)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +573203247267
-
-
Cundinamarca
-
Bogota, Cundinamarca, Kolumbien, 110131
- Rekrutierung
- FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0601)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 573016348173
-
-
Departamento de Córdoba
-
Montería, Departamento de Córdoba, Kolumbien, 230002
- Rekrutierung
- Instituto Médico de Alta Tecnología S.A.S. ( Site 0605)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +573158441430
-
-
Risaralda Department
-
Pereira, Risaralda Department, Kolumbien, 661001
- Rekrutierung
- Oncologos Del Occidente ( Site 0606)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +573123887343
-
-
-
-
Podkarpackie Voivodeship
-
Przemyśl, Podkarpackie Voivodeship, Polen, 37-700
- Rekrutierung
- Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1607)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +48166775000
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekrutierung
- Hospital Universitari Vall d'Hebron ( Site 1700)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34932746000
-
Madrid, Spanien, 28046
- Rekrutierung
- Hospital Universitario la Paz ( Site 1710)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34917277516
-
Madrid, Spanien, 28223
- Rekrutierung
- HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1707)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 913303000
-
Madrid, Spanien, 28040
- Rekrutierung
- Hospital Clinico San Carlos ( Site 1706)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 91 330 30 00
-
Málaga, Spanien, 29010
- Rekrutierung
- H.R.U Malaga - Hospital General ( Site 1708)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 951290000
-
Seville, Spanien, 41009
- Rekrutierung
- Hospital Universitario Virgen Macarena ( Site 1709)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34955008000
-
-
Canary Islands
-
Las Palmas de Gran Canaria, Canary Islands, Spanien, 35016
- Rekrutierung
- Hospital Insular de Gran Canaria ( Site 1704)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 34 928441738
-
-
Gerona
-
Girona, Gerona, Spanien, 17007
- Rekrutierung
- Institut Català d'Oncologia (ICO) - Girona ( Site 1703)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34972225834
-
-
Madrid
-
Majadahonda, Madrid, Spanien, 28222
- Rekrutierung
- Hospital Puerta de Hierro ( Site 1705)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34911917759
-
-
-
-
-
Seoul, Südkorea, 03722
- Rekrutierung
- Severance Hospital Yonsei University Health System ( Site 3601)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8215991004
-
Seoul, Südkorea, 05505
- Rekrutierung
- Asan Medical Center ( Site 3600)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82-2-3010-3214
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Südkorea, 10408
- Rekrutierung
- National Cancer Center ( Site 3603)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 82-31-920-1676
-
Suwon, Kyonggi-do, Südkorea, 16247
- Rekrutierung
- The Catholic University of Korea St. Vincent s Hospital ( Site 3602)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82 31 249 8485
-
-
Taegu-Kwangyokshi
-
Daegu, Taegu-Kwangyokshi, Südkorea, 42601
- Rekrutierung
- Keimyung University Dongsan Hospital ( Site 3605)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 82-53-258-6671
-
-
-
-
-
New Taipei City, Taiwan, 235
- Rekrutierung
- Taipei Medical University Shuang Ho Hospital ( Site 3700)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +886-970-747-515
-
Tainan, Taiwan, 704
- Rekrutierung
- National Cheng Kung University Hospital ( Site 3706)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +886-6-2353535#3120
-
Taipei, Taiwan, 10449
- Rekrutierung
- Mackay Memorial Hospital ( Site 3701)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +886-2543-3535
-
Taipei, Taiwan, 11490
- Rekrutierung
- Tri-Service General Hospital ( Site 3708)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 886-2-87923311#13899
-
Taipei, Taiwan, 106
- Rekrutierung
- National Taiwan University Cancer Center (NTUCC) ( Site 3707)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +886-2-2312-3456
-
-
-
-
-
Adana, Türkei (türkiye), 01250
- Rekrutierung
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1812)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905318328585
-
Adana, Türkei (türkiye), 1140
- Rekrutierung
- Adana Medical Park Seyhan Hastanesi ( Site 1827)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90 539 607 7471
-
Ankara, Türkei (türkiye), 06280
- Rekrutierung
- Ankara Atatürk Sanatoryum Eğitim ve Araştırma Hastanesi ( Site 1825)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +9005360653456
-
Ankara, Türkei (türkiye), 06410
- Rekrutierung
- Hacettepe Universite Hastaneleri ( Site 1810)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90 5415762496
-
Ankara, Türkei (türkiye), 6680
- Rekrutierung
- Liv Hospital Ankara ( Site 1828)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90 5520045315
-
Ankara, Türkei (türkiye), 06800
- Rekrutierung
- Ankara Bilkent Şehir Hastanesi ( Site 1811)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905546820294
-
Istanbul, Türkei (türkiye), 34865
- Rekrutierung
- Kartal Lütfi Kırdar Şehir Hastanesi ( Site 1826)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90 536 719 73 95
-
Malatya, Türkei (türkiye), 44280
- Rekrutierung
- İnönü Üniversitesi Turgut Özal Tıp Merkezi ( Site 1815)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905396194044
-
Mersin, Türkei (türkiye), 33240
- Rekrutierung
- Mersin Sehir Eğitim ve Araştırma Hastanesi ( Site 1824)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905074436940
-
Rize, Türkei (türkiye), 53020
- Rekrutierung
- Recep Tayyip Erdogan University Training and Research Hospital ( Site 1816)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905546815042
-
Sakarya, Türkei (türkiye), 54100
- Rekrutierung
- Sakarya Egitim ve Arastırma Hastanesi ( Site 1817)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905546557924
-
-
-
-
-
Kyiv, Ukraine, 03057
- Rekrutierung
- Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 1915)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380669472333
-
Kyiv, Ukraine, 03126
- Rekrutierung
- Shalimov Institute of Surgery and Transplantation ( Site 1907)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380444081800
-
Kyiv, Ukraine, 03115
- Rekrutierung
- Kyiv City Clinical Oncology Center ( Site 1918)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380503818536
-
-
Cherkasy Oblast
-
Cherkasy, Cherkasy Oblast, Ukraine, 18009
- Rekrutierung
- COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 1904)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380472370123
-
-
Chernivetska Oblast
-
Chernivtsi, Chernivetska Oblast, Ukraine, 58013
- Rekrutierung
- Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" ( Site 1909)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380505144910
-
-
Dnipropetrovsk Oblast
-
Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine, 50000
- Rekrutierung
- Medical Center "Mriya Med-Service" ( Site 1911)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380677490687
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine, 76018
- Rekrutierung
- Communal Non-Commercial Enterprise Prykarpatski Clinical Oncological Center of Ivano-Frankivsk Regio ( Site 1900)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380342507353
-
-
Kirovohrad Oblast
-
Kropyvnytskyi, Kirovohrad Oblast, Ukraine, 25006
- Rekrutierung
- Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 1916)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380969680396
-
Kropyvnytskyi, Kirovohrad Oblast, Ukraine, 25011
- Rekrutierung
- Ukrainian Center of Tomotherapy ( Site 1917)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380958718674
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Ukraine, 79031
- Rekrutierung
- Communal noncommercial enterprise of Lviv regional council "Lviv oncological regional therapeutical ( Site 1908)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380973342609
-
Lviv, Lviv Oblast, Ukraine, 79059
- Rekrutierung
- Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 1902)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380977453295
-
-
Odesa Oblast
-
Odesa, Odesa Oblast, Ukraine, 65025
- Rekrutierung
- Municipal non-profit enterprise'Odesa Regional Clinical Hospital'of Odesa Regional Council ( Site 1913)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380931860876
-
-
Rivne Oblast
-
Rivne, Rivne Oblast, Ukraine, 33010
- Rekrutierung
- ME "Rivne Regional Antitumor Center" Rivne Regional Council ( Site 1912)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380971921000
-
-
Vinnytsia Oblast
-
Vinnytsia, Vinnytsia Oblast, Ukraine, 21029
- Rekrutierung
- Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 1903)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380988936318
-
-
Volyn Oblast
-
Lutsk, Volyn Oblast, Ukraine, 43018
- Rekrutierung
- Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council ( Site 1914)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +380332773100
-
-
-
-
-
Portsmouth, Vereinigtes Königreich, PO6 3LY
- Rekrutierung
- Queen Alexandra Hospital ( Site 2011)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4402392286000
-
-
London, City of
-
London, London, City of, Vereinigtes Königreich, W6 8RF
- Rekrutierung
- Imperial College Healthcare NHS Trust, Charing Cross Hospital ( Site 2012)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4402033111234
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Has a histological/cytological diagnosis of non-small cell lung cancer (NSCLC) with predominantly nonsquamous histology and meets one of the following criteria:
- Has newly diagnosed, treatment-naïve, resectable, clinical Stage IIA-IIIB (N2) NSCLC
- Has completely resected, pathological Stage IIA-IIIB (N2) NSCLC, including those previously treated outside the study with neoadjuvant platinum-doublet chemotherapy plus pembrolizumab or MK-3475A, or those who received adjuvant platinum-doublet chemotherapy.
-
Tumor tissue shows the presence of Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation
-
No more than 12 weeks have elapsed between either the surgery following neoadjuvant treatment or last dose of adjuvant platinum-based chemotherapy and the first dose of investigational adjuvant study intervention.
-
Has no evidence of disease based on postsurgical radiological assessment as documented by contrast-enhanced chest/abdomen computed tomography (or magnetic resonance imaging) within 28 days before randomization
-
Has an Eastern Cooperative Oncology Group performance status of 0 or 1 within 10 days before the first dose of the study intervention
-
Human immunodeficiency virus-infected participants must have well controlled HIV on antiretroviral therapy
-
Participants who are Hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load
-
Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
Exclusion Criteria:
- Has a diagnosis of any 1 of the following tumor types/locations: small cell lung cancer or, for mixed tumors, presence of small cell elements, neuroendocrine tumor with large cell components, sarcomatoid carcinoma, or NSCLC involving the superior sulcus
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, chronic diarrhea)
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within the 6 months preceding study intervention
- Is unable to swallow orally administered medication, or has a gastrointestinal disorder affecting absorption (e.g. gastrectomy, partial bowel obstruction, or malabsorption)
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has an active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has active infection requiring systemic therapy
- Has not adequately recovered from major surgery or has ongoing surgical complications
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Calderasib + MK-3475A
Participants receive calderasib daily (qd) and MK-3475A every 6 weeks (q6w) for up to 9 doses. |
MK-1084 oral tablet
Andere Namen:
Fixed dose coformulated product of hyaluronidase/pembrolizumab administered via SC injection.
Andere Namen:
|
|
Aktiver Komparator: Placebo + MK-3475A
Participants receive placebo qd and MK-3475A q6w for up to 9 doses. |
Placebo oral tablet Fixed dose coformulated product of hyaluronidase/pembrolizumab administered via SC injection.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Disease-free Survival (DFS)
Zeitfenster: Up to ~11 years
|
DFS is the time from randomization to any recurrence (local, locoregional, regional, or distant), occurrence of new primary NSCLC, or death due to any cause, whichever occurs first. |
Up to ~11 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival (OS)
Zeitfenster: Up to ~11 years
|
OS is the time from randomization to death due to any cause. |
Up to ~11 years
|
|
Distant Metastasis-Free Survival (DMFS)
Zeitfenster: Up to ~11 years
|
DMFS is the time from randomization to the first documented distant metastasis or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes. |
Up to ~11 years
|
|
Lung Cancer Specific Survival (LCSS)
Zeitfenster: Up to ~11 years
|
LCSS is the time from randomization to the date of death due to lung cancer. |
Up to ~11 years
|
|
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Zeitfenster: Up to ~11 years
|
Change from baseline in Global health status/QoL score (QLQ-C30 Items 29 and 30). |
Up to ~11 years
|
|
Change from Baseline in the EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Zeitfenster: Up to ~11 years
|
Change from baseline in physical functioning score (QLQ-C30 Items 1 to 5). |
Up to ~11 years
|
|
Change from Baseline in the EORTC-QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Zeitfenster: Up to ~11 years
|
Change from baseline in role functioning score (QLQ-C30 Items 6 and 7). |
Up to ~11 years
|
|
Change from Baseline in the EORTC-QLQ-C30 Dyspnea (Item 8) Score
Zeitfenster: Up to ~11 years
|
Change from baseline in dyspnea (QLQ-C30 Item 8). |
Up to ~11 years
|
|
Change from Baseline in the EORTC-Quality of Life Questionnaire-Lung Cancer 24 (QLQ-LC24) Coughing (Items 31 and 52) Combined Score
Zeitfenster: Up to ~11 years
|
Change from baseline in coughing scores (EORTC QLQ-LC24 Items 31 and 52). |
Up to ~11 years
|
|
Change from Baseline in the EORTC-QLQ-LC24 Chest Pain (Item 40) Score
Zeitfenster: Up to ~11 years
|
Change from baseline in chest pain score (EORTC QLQ-LC24 Item 40). |
Up to ~11 years
|
|
Number of Participants Who Experience an Adverse Event (AE)
Zeitfenster: Up to ~13.5 years
|
Number of participants with ≥1 AE. |
Up to ~13.5 years
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
Zeitfenster: Up to ~13.5 years
|
Number of participants discontinuing from study therapy due to AE. |
Up to ~13.5 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Medical Director, Merck Sharp & Dohme LLC
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 1084-013
- U1111-1312-0627 (Registrierungskennung: UTN)
- 2024-517337-41-00 (Registrierungskennung: EU CT)
- jRCT2071260063 (Registrierungskennung: Japan Registry of Clinical Trials (jRCT))
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .